Only a vaccine with emergency use authorization (EUA) or approval from the FDA can be administered in the U.S. There are currently three vaccines that have received EUA from the FDA and one receiving full approval:

Comirnaty (Pfizer/BioNTech) – EUA granted Dec. 11, expanded Oct. 29, amended Aug. 12; full approval Aug. 23;booster EUA granted Sept. 22, amended Nov. 19

Fully authorized for individuals 16 years of age and older; EUA authorization for individuals 5 to 15 years of age; EUA authorization for booster for all individuals. Not recommended for those who have had a severe allergic reaction after a previous dose of this vaccine or those who have had a severe allergic reaction to any ingredient of this vaccine. Vaccine is delivered in a series of two doses given three weeks apart. Booster dose authorized for receipt six months following two dose regimen and, if over 50 years of age, four months after receiving a first booster dose of any authorized or approved vaccine.

• FDA fact sheet for recipients and caregivers
• FDA EUA Review Memorandum
• FDA approval letter
• Pfizer-BioNTech COVID-19 Vaccine Website for U.S. Healthcare Professionals
• FDA memo on immunocompromised expansion
• FDA press release on booster doses
• FDA press release on EUA for 5-11 year olds
• FDA press release revising booster doses
• FDA press release on second booster doses

Moderna – EUA granted Dec. 18, amended Aug. 12; booster EUA granted Oct. 20, amended Nov. 19; full approval granted Jan. 31

EUA authorized for individuals 18 years of age or older. Vaccine is delivered in a series of two doses given 28 days apart. Booster dose authorized for receipt six months following two dose regimen and, if over 50 years of age, four months after receiving a first booster dose of any authorized or approved vaccine.

• FDA briefing document
• FDA fact sheet for recipients and caregivers
• FDA EUA Review Memorandum
• FDA approval press release
• Moderna Vaccine Information
• FDA memo on immunocompromised expansion
• FDA press release on booster doses
• FDA press release revising booster doses
• FDA press release on second booster doses

Johnson & Johnson (Janssen Biotech, Inc.) – EUA granted Feb. 27; booster EUA granted Oct. 20, amended Nov. 19

Authorized for individuals 18 years of age or older. Vaccine is delivered as a single intramuscular injection. Booster dose authorized for receipt six months following initial dose.

• FDA briefing document
• FDA fact sheet for recipients and caregivers
• FDA EUA Review Memorandum
• FDA press release on booster doses
• FDA press release revising booster doses

Additional information on vaccines is available through the World Health Organization.

AAOMS is providing this list of resources to assist members with the evolving changes with COVID-19 coding and billing and related services.

AAOMS COVID-19 Resources

• Coding and Billing for COVID-19 Testing, Vaccines and PPE
• COVID-19 Guide for OMS Practices
• COVID-19 Guidance and FAQs

ADA and AMA COVID-19 Coding Resources

• ADA CDT Coding and Contract Guidance
• AMA CPT Coding Guidance

The CARES Act suspended payments, principal and interest (without penalty to the borrower) for all federally owned loans through May 1. The U.S. Department of Education’s office of Federal Student Aid has developed an FAQ webpage with more information.